SL Science Presented New Glioblastoma Therapy Data
Researchers showed that specific immune cells can target chemotherapy-resistant brain tumor cells.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you believe new cell therapies offer a promising path for treating resistant cancers?
SL Science presented preclinical findings demonstrating that γδ T cells successfully target chemotherapy-resistant, MGMT-positive glioblastoma cells. The data, shared at a recent medical conference, indicates these cells can reduce tumor size and improve survival rates.
Why it matters
Glioblastoma remains difficult to treat because MGMT-positive cells effectively reverse standard chemotherapy-induced DNA damage. This research offers a potential alternative therapy by utilizing immune cells that recognize stress signals rather than specific antigens.
The study utilized three distinct glioblastoma cell lines, U87MG, T98G, and LN229, to demonstrate superior cancer-killing activity compared to conventional alpha-beta T cells. These γδ T cells recognize general stress signals expressed on cancer cells.
The players
SL Science
This biotechnology company is headquartered in Taipei, Taiwan, and focuses on developing novel cancer therapies.
Taipei Medical University
This educational and research institution partnered with SL Science to conduct the preclinical glioblastoma study.
The details
In an intracranial glioblastoma model, the experimental therapy significantly reduced tumor size and prolonged survival. The researchers conducted this analysis in collaboration with Taipei Medical University, JY BioMed, and HeXun Biosciences.
Timeline
July 2026: Research on in vivo tumor growth was presented in Melbourne.
August 2026: Clinical development requirements were published.
September 24-26, 2026: The 85th Annual Meeting of the Japanese Cancer Association was held.
The Big Picture
This discovery challenges the current reliance on standard chemotherapy for MGMT-positive glioblastoma, which is notoriously resistant to DNA-damaging drugs. By moving toward stress-signal recognition, the research potentially shifts the focus of brain cancer treatment paradigms.
While this research is currently preclinical, it eventually aims to provide new treatment options for patients with chemotherapy-resistant brain tumors. Future clinical trials will determine whether these findings can safely translate into human therapeutic applications.
The takeaway
This study highlights the potential for using immune cells that target general cellular stress to bypass traditional treatment resistance in aggressive brain cancers. Patients and their families should note that these findings are early-stage and not yet available for clinical use.
Further reading
For more information on current developments, visit the Cancer section.
More information
Review additional information about the study and the company on the SL Science company website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe new cell therapies offer a promising path for treating resistant cancers?
